Resveratrol review finds selective metabolic changes, but no consistent weight change
Pooled trials reported improvements in some metabolic and inflammatory measures, while several body-size and liver measures showed no consistent change.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Across trials in adults with obesity-related metabolic disorders or risk factors, resveratrol showed improvements in selected measures, including insulin resistance, cholesterol and blood pressure. Body weight and liver fat did not change consistently. These findings concern measured risk factors; the abstract does not establish that supplementation prevents diabetes, cardiovascular disease or other long-term illness.
The abstract omits numerical effect sizes, confidence intervals, comparator details and study durations. This abstract-based account cannot judge how large the changes were, and it does not identify an optimal dose.
Which measures changed
The authors report statistically significant reductions in insulin resistance, total and LDL cholesterol, triglycerides, blood pressure and selected inflammation markers. HDL cholesterol and several measures of body size or liver health showed no consistent changes.
What the pattern means
The authors characterize the metabolic and inflammatory benefits as modest and selective. Effects varied with dose and duration, but the abstract provides no estimates that would justify choosing a dose or claiming broad disease prevention.
The original publication
Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases.
Shen CY, Li CP, Yu JT et al.
In Vivo · 2026
- PubMed ID
- 41760304
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.